SHENYANG, China, Jan. 28 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX - News; “3SBio” or the “Company”), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced the appointment of Kevin Teo to the position of Chief Financial Officer effective January 28, 2008. Mr. Teo will replace Clara Mak, who is resigning for personal reasons. To assist with the transition, Ms. Mak will stay on with the Company until February 29, 2008.
Dr. Jing Lou, CEO of 3SBio, commented, “I am pleased to welcome Kevin Teo to 3SBio’s senior management team. After a focused search, Kevin emerged as the clear choice to fill the role of Chief Financial Officer at 3SBio, as he brings with him a wealth of experience in finance and accounting with some of the leading companies in the region. I have full confidence in Kevin’s ability to transition smoothly into the role of the CFO of 3SBio, and we look forward to his contributions and leadership as we continue to build 3SBio into the leading biotech company in China. Clara Mak, who has been an integral part of the team, has led 3SBio through the IPO process and on to continued growth as a public company. Her financial leadership has also been instrumental in helping the company successfully position itself for continued solid performance and she will be missed. We wish her the best in her future endeavors.”
Mr. Teo, 42, brings to 3SBio over 20 years of relevant experience, having held a number of senior finance and accounting positions in the energy and technology industries throughout Asia. Most recently, he served as Group Business Controller at East Asia Power (Xiamen), where he oversaw and managed finance and accounting teams located in Hong Kong, Singapore, Jakarta, Xiamen, Nanjing and Beijing. His responsibilities included, but were not limited to, the implementation of company-wide internal control procedures and policies, oversight of the company’s monthly financial statements and position, liaison with corporate departments, interaction with external parties and advisors, and coordination of annual audits at subsidiary and group levels.
Prior to his employment with East Asia Power (Xiamen), Mr. Teo held senior roles at Huawei Technologies Co. Ltd. (Shenzhen), Siemens Malaysia Sdn. Bhd., Siemens Cerberus Sdn. Bhd., Wetlands International - Asia Pacific, Chua Song Seng Sdn. Bhd., and Anuarul Azizan Chew & Co. Mr. Teo received a London Chamber of Commerce and Industry Third Level Group Diploma in Cost Accounting and a Pitman Certificate in Advanced Accounting in 1989. He is also a member of the Association of Chartered Certified Accountants since 1995 and received a certificate in International Financial Reporting Standards in 2006. He attended the Master of Laws in International Business Law accredited by School of Law, Staffordshire University in the U.K. He has been a member of the Malaysian Institute of Accountants since 1996.
About 3SBio Inc.
3SBio Inc. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China. For more information, please visit 3SBio on the web at http://www.3sbio.com .
For more information, please contact:
Investor Contact: Clara Mak, CFO 3SBio Inc. Tel: +86-24-2581-1820
Investor Relations(HK): Ruby Yim Taylor Rafferty Tel: +852-3196-3712
Investor Relations(US): Mahmoud Siddig Taylor Rafferty Tel: +1-212-889-4350
Media Contact: John Dooley Taylor Rafferty Tel: +1-212-889-4350
Source: 3SBio Inc.
